The Technology and Life Sciences team advised Valo Health in the final closing of its Series B at $300 million, including a $110 million investment from Koch Disruptive Technologies. This brings the overall funding of Valo to over $450 million. With this investment, Valo will continue to scale its Opal Computational PlatformTM, the first-of-its-kind fully integrated end-to-end platform that combines machine learning-driven computational capabilities and patient data to develop first-in-class and best-in-class therapeutic programs across major disease areas.
Valo Health is a technology company that is using human-centric data and machine learning computation to transform the drug discovery and development process. As a digitally native company, Valo is the first to fully integrate human-centric data across the entire drug development lifecycle into a single unified architecture, thereby accelerating the discovery and development of life-changing drugs while simultaneously reducing the cost, time, and failure rate.
For additional details on the funding round, please read the press release.